aTyr Pharma (LIFE) News Today

aTyr Pharma (NASDAQ:LIFE) Stock Price Passes Above 200 Day Moving Average of $1.65

aTyr Pharma, Inc. (NASDAQ:LIFE - Get Free Report) Director Timothy Coughlin acquired 50,000 shares of the firm's stock in a transaction that occurred on Thursday, May 30th. The stock was purchased at an average price of $1.75 per share, with a total value of $87,500.00. Following the completion of the acquisition, the director now owns 56,000 shares in the company, valued at $98,000. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

aTyr Pharma, Inc. (NASDAQ:LIFE - Get Free Report) was the target of a large decline in short interest in the month of May. As of May 15th, there was short interest totalling 343,400 shares, a decline of 46.0% from the April 30th total of 636,200 shares. Based on an average trading volume of 563,900 shares, the short-interest ratio is presently 0.6 days.

aTyr Pharma, Inc. (NASDAQ:LIFE - Get Free Report) was the target of a significant growth in short interest in the month of April. As of April 30th, there was short interest totalling 636,200 shares, a growth of 66.1% from the April 15th total of 383,100 shares. Based on an average daily volume of 572,400 shares, the short-interest ratio is currently 1.1 days.

HC Wainwright restated a "buy" rating and issued a $35.00 target price on shares of aTyr Pharma in a research note on Friday.

aTyr Pharma (NASDAQ:LIFE - Get Free Report) posted its quarterly earnings data on Thursday. The biotechnology company reported ($0.23) EPS for the quarter, beating the consensus estimate of ($0.24) by $0.01. The company had revenue of $0.24 million during the quarter, compared to the consensus estimate of $0.11 million.

Stonepine Capital Management LLC lowered its position in aTyr Pharma, Inc. (NASDAQ:LIFE - Free Report) by 89.6% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 482,258 shares of the biotechnology

aTyr Pharma, Inc. (NASDAQ:LIFE - Get Free Report) saw a significant increase in short interest during the month of March. As of March 15th, there was short interest totalling 289,300 shares, an increase of 167.4% from the February 29th total of 108,200 shares. Based on an average daily volume of 521,200 shares, the short-interest ratio is currently 0.6 days.

HC Wainwright reaffirmed a "buy" rating and set a $35.00 price target on shares of aTyr Pharma in a research report on Friday.

Royal Bank of Canada reduced their target price on aTyr Pharma from $19.00 to $16.00 and set an "outperform" rating on the stock in a report on Friday.

aTyr Pharma (NASDAQ:LIFE) Share Price Crosses Above 200 Day Moving Average of $1.51

HC Wainwright restated a "buy" rating and set a $35.00 price target on shares of aTyr Pharma in a research note on Wednesday.